GlassScriptPhysician profile
Michael A Scola
NPI 1245228295
$505,548.04
in general payments reported to CMS, 2019-2025
60 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113K · 2020: $79K · 2021: $67K · 2022: $69K · 2023: $48K · 2024: $53K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Consulting Fee: $28K · Travel and Lodging: $20K · Food and Beverage: $11K · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,526.25 |
| Consulting Fee | $27,742.00 |
| Travel and Lodging | $19,792.52 |
| Food and Beverage | $11,354.15 |
| Education | $294.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $437,949.32 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Janssen Pharmaceuticals, INC | $27,260.60 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $9,411.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $4,928.83 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $4,620.09 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,768.87 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Cti Biopharma Corp. | $2,590.49 | 2022 | |
| Aveo Pharmaceuticals, INC. | $1,815.00 | 2023 | Fotivda |
| Abbvie INC. | $1,631.17 | 2020-2025 | Venclexta |
| Celgene Corporation | $1,576.03 | 2020-2025 | Pomalyst, Reblozyl, Opdualag |
| Pfizer INC. | $1,130.53 | 2019-2025 | |
| Seagen INC. | $1,045.82 | 2019-2025 | Tukysa, Adcetris, Padcev |
| Merck Sharp & Dohme LLC | $869.67 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $762.15 | 2019-2025 | Enhertu, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $603.80 | 2019-2025 | Calquence, Lynparza |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $568.09 | 2020-2025 | Padcev, Xospata |
| Janssen Biotech, INC. | $561.26 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Gilead Sciences, INC. | $517.95 | 2019-2025 | Trodelvy |
| Eisai INC. | $451.00 | 2019-2025 | |
| Amgen INC. | $315.21 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $279.70 | 2019-2024 | Libtayo |
| Mirati Therapeutics, INC. | $276.57 | 2023-2024 | Krazati |
| Genentech USA, INC. | $262.76 | 2019-2023 | Lunsumio, Venclexta |
| Kite Pharma, INC. | $224.95 | 2020-2025 | Yescarta |
| Karyopharm Therapeutics INC. | $217.70 | 2022-2023 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $187.63 | 2019-2023 | Vpriv |
| Immunogen, INC. | $154.09 | 2023-2024 | Elahere, Elahere |
| Pharmacyclics LLC, An Abbvie Company | $124.55 | 2021-2022 | |
| Geron Corporation | $114.44 | 2025 | Rytelo |
| Foundation Medicine, INC. | $112.04 | 2023 | |
| Jazz Pharmaceuticals INC. | $92.47 | 2019-2020 | |
| Array Biopharma INC | $91.14 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Lilly USA, LLC | $88.93 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Pharmacosmos Therapeutics INC. | $79.25 | 2022-2024 | Monoferric |
| Taiho Oncology, INC. | $63.87 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $61.32 | 2019-2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.37 | 2019-2021 | |
| Eusa Pharma (US) LLC | $58.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.83 | 2019-2024 | |
| Exelixis INC. | $50.62 | 2019-2025 | Cabometyx |
| Genmab U.S., INC. | $48.88 | 2022-2024 | Epkinly |
| Emd Serono, INC. | $47.58 | 2023-2025 | Tepmetko |
| Epizyme, INC. | $43.77 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $37.15 | 2025 | Pyrukynd |
| Stemline Therapeutics INC. | $34.94 | 2024-2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $33.33 | 2022 | |
| Servier Pharmaceuticals LLC | $31.62 | 2023-2024 | |
| Morphosys, US INC. | $30.42 | 2022 | |
| Rigel Pharmaceuticals, INC. | $27.36 | 2019-2021 | |
| Acrotech Biopharma INC. | $24.92 | 2021 | |
| Puma Biotechnology, INC. | $22.84 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Macrogenics, INC. | $18.12 | 2022 | |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Acceleron Pharma, INC. | $14.75 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.47 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.06 | 2020 | |
| Duchesnay USA Incorporated | $14.04 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.61 | 2019 | |
| Tersera Therapeutics LLC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.